Clinical trial
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
NCT00123877 · Gem Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00123877 |
|---|---|
| Title | Study of GPX-100 in the Treatment of Metastatic Breast Cancer |
| Official title | Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer |
| Lead sponsor | Gem Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastasis |
| Intervention type | Drug |
| Interventions | GPX-100 (13-deoxydoxorubicin) |
| Enrollment | 40 |
| Start date | Mar 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Jul 26, 2005 |
| Last update posted | Jan 9, 2007 |
| Countries | Bulgaria, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: